News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Johnson & Johnson: In Talks To Resolve US Probe Of Risperdal Marketing
November 11, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Wall Street Journal -- Johnson & Johnson (JNJ) said it's in discussions with the government to resolve a long-running investigation of whether it improperly marketed the antipsychotic Risperdal.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
FDA
US government launches AI-driven programs to overhaul clinical trials
October 1, 2026
·
4 min read
·
Gabrielle Masson
Legal
Nektar prevails in legal battle with Lilly over broken rezpeg partnership
September 25, 2026
·
2 min read
·
Annalee Armstrong
China
China’s surging biotech sector represents both competition and lifeline for the US
September 23, 2026
·
8 min read
·
Shawna Williams
China
FDA raises bar for foreign site inspections as China trials surge
September 2, 2026
·
4 min read
·
Heather McKenzie